Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!
Boston Scientific senior vice president Jeff Mirviss writes a scathing criticism of the device tax and applauds Congressional efforts to repeal the 2.3% levy. Jeff Mirviss, the global president and SVP of Boston Scientific (NYSE:BSX), penned a scathing criticism of the medical device tax on the alumni blog of the University of St. Thomas. Mirviss applauded Rep. Erik Paulsen (R-Minn.) for his bipartisan bill that would repeal the tax, a levy which Mirviss said will hamper innovation and growth in the Twin Cities “Medical Alley.”
Help employers find you! Check out all the jobs and post your resume.
